[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pulmonx Corp (LUNG)

Pulmonx Corp (LUNG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,796
  • Shares Outstanding, K 42,237
  • Annual Sales, $ 90,500 K
  • Annual Income, $ -54,000 K
  • EBIT $ -52 M
  • EBITDA $ -51 M
  • 60-Month Beta 0.28
  • Price/Sales 0.60
  • Price/Cash Flow N/A
  • Price/Book 1.18

Options Overview Details

View History
  • Implied Volatility 210.66% (+25.33%)
  • Historical Volatility 70.65%
  • IV Percentile 42%
  • IV Rank 21.26%
  • IV High 651.31% on 03/20/26
  • IV Low 91.70% on 06/23/25
  • Expected Move (DTE 1) 0.9520 (75.86%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 4
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 1,457
  • Open Int (30-Day) 925
  • Expected Range 0.3030 to 2.2070

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.28
  • Number of Estimates 2
  • High Estimate $-0.27
  • Low Estimate $-0.29
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +2.87%
on 06/15/26
1.7150 -26.82%
on 06/01/26
-0.0150 (-1.18%)
since 05/15/26
3-Month
1.1300 +11.06%
on 03/30/26
1.7150 -26.82%
on 06/01/26
-0.3650 (-22.53%)
since 03/17/26
52-Week
1.1300 +11.06%
on 03/30/26
3.8800 -67.65%
on 07/23/25
-1.4550 (-53.69%)
since 06/17/25

Most Recent Stories

More News
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.2500 (-0.40%)
Pulmonx Reports First Quarter 2026 Financial Results

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.2500 (-0.40%)
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the...

LUNG : 1.2500 (-0.40%)
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...

LUNG : 1.2500 (-0.40%)
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.2500 (-0.40%)
Pulmonx Announces Closing of up to $60 Million Credit Facility

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.2500 (-0.40%)
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it...

LUNG : 1.2500 (-0.40%)
Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today...

LUNG : 1.2500 (-0.40%)
Pulmonx Reports Third Quarter 2025 Financial Results

REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported...

LUNG : 1.2500 (-0.40%)
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive Officer Derrick Sung, former Pulmonx Chief Financial Officer,...

LUNG : 1.2500 (-0.40%)

Business Summary

Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 1.3967
2nd Resistance Point 1.3633
1st Resistance Point 1.3067
Last Price 1.2500
1st Support Level 1.2167
2nd Support Level 1.1833
3rd Support Level 1.1267

See More

52-Week High 3.8800
Fibonacci 61.8% 2.8295
Fibonacci 50% 2.5050
Fibonacci 38.2% 2.1805
Last Price 1.2500
52-Week Low 1.1300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.